Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Bispecific anti-CCL2 antibodies
US11739142B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11739142-B2 |
| Application number | US-202017123465-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 16, 2020 |
| Priority date | Dec 18, 2019 |
| Publication date | Aug 29, 2023 |
| Grant date | Aug 29, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated bispecific antibody comprising a first antigen-binding site that binds to a first epitope on human CCL2 and a second antigen-binding site that binds a second epitope on human CCL2, wherein A) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:71; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or B) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:71; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:91; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or C) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:71; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:94; or D) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:72; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:94; or E) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:73; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or F) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:73; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:94; or G) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:73; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:92; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or H) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:73; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:91; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or I) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:72; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or J) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:72; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:92; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or K) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:72; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:91; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or L) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:74; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or M) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:74; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:90; and a VL domain comprising the amino acid sequence of SEQ ID NO:94; or N) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:74; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:92; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or O) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:74; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:91; and a VL domain comprising the amino acid sequence of SEQ ID NO:93; or P) i) said first antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:71; and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and ii) said second antigen-binding site comprises a VH domain comprising the amino acid sequence of SEQ ID NO:92; and a VL domain comprising the amino acid sequence of SEQ ID NO:93. 2. A composition comprising the bispecific antibody of claim 1 , and a carrier.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Complementarity determining region [CDR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11739142B2 cover?
- The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).